Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated Followed by 4 Cycles of BEACOPP Baseline with Our without Radiotherapy in Patients in Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised HD12 Trial of the German Hodgkin Study Group (GHSG)

被引：0

作者：

Diehl, Volker

Haverkamp, Heinz ^{[1
]}

Mueller, Rolf Peter ^{[2
]}

Eich, Hans Theodor ^{[2
]}

Mueller-Hermelink, Hans Konrad ^{[3
]}

Cerny, Thomas ^{[4
]}

Markova, Jana ^{[5
]}

Ho, Anthony ^{[6
]}

Kanz, Lothar ^{[7
]}

Greil, Richard ^{[8
]}

Hiddemann, Wolfgang ^{[9
]}

Engert, Andreas ^{[2
]}

机构：

[1] Univ Cologne, Dept Internal Med 1, GHSG, Cologne, Germany

[2] Univ Cologne, Dept Radiotherapy, Cologne, Germany

[3] Univ Wurzburg, Dept Pathol, Wurzburg, Germany

[4] Kanionsspital St Gallen, Dept Oncol, St Gallen, Switzerland

[5] Fak Nemocnice, Clin Hematol, Prague, Czech Republic

[6] Univ Heidelberg, Dept Hematol & Oncol, Heidelberg, Germany

[7] Univ Tubingen, D-72074 Tubingen, Germany

[8] Salzburg Univ, Dept Internal Med 3, A-5020 Salzburg, Austria

[9] Univ Munic, Dept Internal Med 3, Munic, Germany

来源：

BLOOD | 2008年 / 112卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：552 / 553

页数：2

共 50 条

[1] Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with our without radiotherapy in patients in advanced stage Hodgkin Lymphoma (HL): Final analysis of the randomised HD12 trial of the German Hodgkin Study Group (GHSG)
Eich, H. T.
Mueller, R-P.
Haverkamp, H.
Gossmann, A.
Staar, S.
Kriz, J.
Lukas, P.
Willich, N.
Engenhart-Cabillic, R.
Engert, A.
STRAHLENTHERAPIE UND ONKOLOGIE, 2009, 185 : 26 - 26
[2] Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients in advanced stage Hodgkin lymphoma (HL): Final analysis of the HD12 trial of the German Hodgkin Study Group (GHSG)
Diehl, V.
Haverkamp, H.
Mueller, R.
Mueller-Hermelink, H.
Cerny, T.
Markova, J.
Ho, A. D.
Kanz, L.
Greil, R.
Engert, A.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[3] Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated followed by 4 Cycles of BEACOPP Baseline with or without Radiotherapy in Patients in Advanced-stage Hodgkin Lymphoma (HL): Final Analysis of the Randomized HD12 Trial of the German Hodgkin Study Group (GHSG)
Eich, H.
Engert, A.
Haverkamp, H.
Staar, S.
Kriz, J.
Engenhart-Cabillic, R.
Lukas, P.
Willich, N.
Diehl, V.
Mueller, R.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S3 - S4
[4] Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group
Borchmann, Peter
Haverkamp, Heinz
Diehl, Volker
Cerny, Thomas
Markova, Jana
Ho, Anthony D.
Eich, Hans-Theodor
Mueller-Hermelink, Hans Konrad
Kanz, Lothar
Greil, Richard
Rank, Andreas
Paulus, Ursula
Smardova, Lenka
Huber, Christoph
Doerken, Bernd
Nerl, Christoph
Krause, Stefan W.
Mueller, Rolf-Peter
Fuchs, Michael
Engert, Andreas
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4234 - 4242
[5] HD12 randomised trial comparing 8 dose-escalated cycles of BEACOPP with 4 escalated and 4 baseline cycles in patients with advanced stage Hodgkin lymphoma (HL): An analysis of the german Hodgkin lymphoma study group (GHSG), University of Cologne, D-50924 Cologne, Germany.
Engert, Andreas
Franklin, Jeremy
Mueller, Rolf-Peter
Eich, Hans-Theodor
Gossmann, Axel
Mueller-Hermelink, Hans Konrad
Cemy, Thomas
Markova, Jana
Ho, Anthony D.
Kanz, Lothar
Greil, Richard
BLOOD, 2006, 108 (11) : 33A - 33A
[6] TREATMENT OF ADVANCED STAGE HODGKIN LYMPHOMA WITH 4 CYCLES OF BEACOPP ESCALATED FOLLOWED BY 4 CYCLES OF BEACOPP BASELINE: LONG-TERM RESULTS FROM A SINGLE CENTRE
Stepankova, P.
Belada, D.
Sykorova, A.
Maly, J.
HAEMATOLOGICA, 2010, 95 : S24 - S25
[7] Results of the third interim analysis of the HD12 trial of the GHSG: 8 courses of escalated BEACOPP versus 4 escalated and 4 baseline courses of BEACOPP with or without additive radiotherapy for advanced stage Hodgkin's lymphoma.
Diehl, V
Schiller, P
Engert, A
Wolf, J
Josting, A
Mueller, RP
Eich, HT
Gossmann, A
Mueller-Hermelink, HK
Franklin, J
Cerny, T
Markova, J
Ho, AD
Kanz, L
Greil, R
Hiddemann, W
BLOOD, 2003, 102 (11) : 27A - 28A
[8] Are four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline an appropriate treatment option for patients with advanced stage Hodgkin's lymphoma? A single-center retrospective analysis
Stepankova, P.
Belada, D.
Zavrelova, A.
Sykorova, A.
Smolej, L.
Maly, J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 68 - 68
[9] Dose-Intensified Combined Modality Treatment with 2 Cycles of BEACOPP Escalated Followed by 2 Cycles of ABVD and Involved Field Radiotherapy (IF-RT) Is Superior to 4 Cycles of ABVD and IF-RT in Patients with Early Unfavourable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial
Borchmann, Peter
Engert, Andreas
Pluetschow, Annette
Fuchs, Michael
Markova, Jana
Lohri, Andreas
Kral, Zdenek
Greil, Richard
Topp, Max
Villalobos, Matthias
Zijlstra, Jose
Soekler, Martin
Stein, Harald
Eich, Hans Theodor
Mueller, Rolf Peter
Diehl, Volker
BLOOD, 2008, 112 (11) : 143 - 143
[10] 10-year results of the HD9 trial of the German Hodgkin study group (GHSG) comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma
Diehl, V.
Franklin, J.
Fuchs, M.
Pfistner, B.
Engert, A.
ANNALS OF ONCOLOGY, 2008, 19 : 135 - 135

← 1 2 3 4 5 →